Jump to content

Do you want up to date information about Scleroderma? Check out our Medical pages at www.sclero.org for all your Scleroderma questions!


FDA Clears Uptravi (Selexipag) for Pulmonary Arterial Hypertension.

pah treatments

  • Please log in to reply
No replies to this topic

#1 Joelf


    Star Ruby Member

  • ISN Root Admin
  • PipPipPipPipPipPipPipPipPipPipPipPipPip
  • 4,552 posts
  • Location:West Sussex

Posted 09 March 2016 - 06:32 AM

FDA Clears Uptravi (Selexipag) for Pulmonary Arterial Hypertension.


Uptravi (Selexipag) was shown to be effective in reducing hospitalization for PAH and reducing the risks of disease progression compared to placebo. FDA, 12/22/2015. (Also see Treatments for Pulmonary Hypertension)


This item was posted in the ISN Newsroom. Please check the newsroom daily for updates on scleroderma and other related articles.

Jo Frowde
ISN Assistant Webmaster
ISN Sclero Forums Manager
ISN News Manager

ISN Hotline Support Specialist
ISN Chat Host
International Scleroderma Network (ISN)